# Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

> **NCT04094506** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 9 (actual)

## Conditions studied

- Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies

## Interventions

- **DRUG:** ASP1948

## Key facts

- **NCT ID:** NCT04094506
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-30
- **Primary completion:** 2022-02-02
- **Final completion:** 2022-02-02
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04094506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04094506, "Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04094506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*